GSK, Rockville, MD, USA, United States
Disclosure information not submitted.
1D-02 - Risk of Incident Supraventricular Tachycardia Following Exposure to Recombinant Zoster Vaccine in Adults ≥50 Years of Age in the United States
Sunday, August 24, 202510:45 AM - 11:00 AM ET
1D-03 - Recombinant Zoster Vaccine and Risk of Incident Guillain-Barré Syndrome in US Adults ≥ 65 Years of Age
Sunday, August 24, 202511:00 AM - 11:15 AM ET
